World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
34621
World Ranking
15404
National Ranking
228

Overview

Jens Huober is affiliated with Kantonsspital St. Gallen in Switzerland. Their research primarily focuses on oncology within the broader field of medicine, with a significant number of publications also contributing to biochemistry, genetics, and molecular biology.

Their main areas of study concentrate on cancer, particularly breast cancer, with a substantial emphasis on treatment studies and therapeutic approaches. Key research topics include:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Breast Lesions and Carcinomas

Jens Huober has contributed to numerous scientific articles in prominent journals. Frequent publication venues include:

  • Annals of Oncology
  • Cancer Research
  • Geburtshilfe und Frauenheilkunde
  • Senologie - Zeitschrift für Mammadiagnostik und -therapie
  • Clinical Cancer Research

Recent notable papers include:

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021, Annals of Oncology)
  • Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials (2021, The Lancet Oncology)
  • Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial (2022, The Lancet Oncology)
  • Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study (2021, Annals of Oncology)
  • Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo (2020, Annals of Oncology)

Collaborative work is an essential aspect of their research, featuring frequent co-authors such as:

  • Andreas Schneeweiß
  • Peter A. Fasching
  • Michael Untch
  • Sibylle Loibl
  • Jens-Uwe Blohmer

The subfields of study in which they have substantial contributions include:

  • Oncology
  • Cancer Research
  • Pulmonary and Respiratory Medicine
  • Radiology, Nuclear Medicine and Imaging
  • Pathology and Forensic Medicine

Best Publications

  • Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

    Gunter von Minckwitz;Michael Untch;Jens-Uwe Blohmer;Serban D. Costa

  • Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

    Carsten Denkert;Gunter von Minckwitz;Silvia Darb-Esfahani;Bianca Lederer

  • MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

    Matthew P. Goetz;Masakazu Toi;Mario Campone;Joohyuk Sohn

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

    Gunter von Minckwitz;Andreas Schneeweiss;Sibylle Loibl;Christoph Salat

  • Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

    Sibylle Loibl;Joyce O'Shaughnessy;Michael Untch;William M Sikov

  • Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

    Michael Untch;Mahdi Rezai;Sibylle Loibl;Peter A. Fasching

  • A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

    S. Loibl;M. Untch;N. Burchardi;J. Huober

  • Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

    Gunter von Minckwitz;Holger Eidtmann;Mahdi Rezai;Peter A. Fasching

  • Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial

    Sabine Riethdorf;Volkmar Müller;Liling Zhang;Thomas Rau

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

    H J Burstein;G Curigliano;B Thürlimann;W P Weber

  • Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial

    Philipp Harter;Andreas du Bois;Maik Hahmann;Annette Hasenburg

  • Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

    Michael Untch;Sibylle Loibl;Joachim Bischoff;Holger Eidtmann

  • Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

    I.E. Krop;N.U. Lin;K. Blackwell;E. Guardino

  • Response-Guided Neoadjuvant Chemotherapy for Breast Cancer

    Gunter von Minckwitz;Jens Uwe Blohmer;Serban Dan Costa;Carsten Denkert

  • Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

    Stephen R D Johnston;Nadia Harbeck;Roberto Hegg;Masakazu Toi

  • Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.

    Eric Hahnen;Bianca Lederer;Jan Hauke;Sibylle Loibl

  • Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.

    Carsten Denkert;Fenja Seither;Andreas Schneeweiss;Theresa Link

  • Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

    Jens Huober;Gunter von Minckwitz;Carsten Denkert;Hans Tesch

  • Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308))

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

Frequent Co-Authors

Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Peter A. Fasching
Peter A. Fasching University of Erlangen-Nuremberg
Sibylle Loibl
Sibylle Loibl Goethe University Frankfurt
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation
Gunter von Minckwitz
Gunter von Minckwitz University of Ulm
Carsten Denkert
Carsten Denkert Philipp University of Marburg
Volkmar Müller
Volkmar Müller Universität Hamburg
Tanja Fehm
Tanja Fehm Heinrich Heine University Düsseldorf
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA doesn’t always have to begin with a traditional MD. Many students choose alternative online pathways that offer flexible schedules and faster progression. A popular choice for registered nurses wanting to advance is enrolling in online rn-bsn programs without clinicals. These programs allow working professionals to complete their degrees without hands-on clinical requirements, making them ideal for busy practitioners.

For those looking to take their nursing education even further, there are also dnp programs online. Some universities offer online dnp programs without clinicals, removing clinical hurdles while still providing a pathway to advanced leadership roles in nursing.

If you’re just beginning your healthcare journey, consider fast-tracking your entry into nursing with a fast lpn program online. These accelerated options quickly prepare students for licensure and employment, offering a flexible alternative to traditional classroom-based education.

Whether you’re upskilling or just starting out, these online pathways make it easier than ever to pursue a rewarding healthcare career in the US.

Best Scientists Citing Jens Huober

Trending Scientists

Recently Published Articles